Adarza News

24 06, 2020

Adarza’s Ziva provides window into immune response to COVID-19 and other pathogens

2020-06-24T15:08:14-05:00June 24th, 2020|

Adarza Biosystems Inc.’s Ziva platform can simultaneously detect hundreds of proteins, antibodies, or substrates from a single drop of blood, plasma or serum, providing insight into an individual’s immune response. That could be critical for both surveillance and diagnostic purposes as the nation prepares for a likely second wave of the novel coronavirus in the fall when multiple respiratory pathogens will be circulating.

6 02, 2020

St. Louis biotech startup raises $25M as it prepares for commercialization

2020-02-06T14:03:46-06:00February 6th, 2020|

Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.

5 02, 2020

Adarza raises $25 million, moves toward commercialization

2020-02-06T13:57:15-06:00February 5th, 2020|

Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.

4 02, 2020

Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development

2020-02-06T13:37:24-06:00February 4th, 2020|

Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.

1 05, 2019

Adarza BioSystems to reveal ZIVA platform at AAI 2019

2019-05-02T18:39:13-05:00May 1st, 2019|

Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 - 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.

23 05, 2018

St. Louis Business Journal: St. Louis biotech startup to launch products in 2019

2018-05-23T15:23:03-05:00May 23rd, 2018|

Once Adarza's products launch in the second quarter of 2019, it will be one of a handful of local life sciences startups to have done so.

23 05, 2018

Adarza Sets Stage for Commercialization

2018-05-23T15:01:45-05:00May 23rd, 2018|

Adarza Biosystems, Inc., a biotechnology company developing a novel protein and biomolecule detection platform, announced today that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019.

24 01, 2017

St. Louis Business Journal: RiverVest leads $17M investment in Adarza, brings on new president

2017-09-11T12:53:54-05:00January 24th, 2017|

RiverVest leads $17 million investment in Adarza, brings on new president